Cough in Patients With Lung Cancer: A Longitudinal Observational Study of Characterization and Clinical Associations

Chest: The Journal of Circulation, Respiration and Related Systems

Katie Baker^8¹  Kimberley J. Holt^7²  Fiona H. Blackhall^2,3³  Alex Molassiotis^4⁴  Danielle Yuill^7⁵  Rachel Dockry^7⁶  Amélie S.M. Harle^1,2⁷  Jaclyn A. Smith^7,9⁸  Janelle Yorke^5,6⁹ 

[1] Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, England^8;Department of Christie Patient Centred Research, The Christie NHS Foundation Trust, Manchester, England^6;Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, England^2;Division of Cancer Sciences, University of Manchester, Manchester, England^3;Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, England^7;Division of Nursing, Midwifery and Social Work, School of Health Sciences, University of Manchester, Manchester, England^5;Dorset Cancer Centre, Poole NHS Foundation Trust, Poole, England^1;Manchester University NHS Foundation Trust, Manchester, England^9;School of Nursing, The Hong Kong Polytechnic University, Hong Kong^4

关键词: assessment;    cough;    lung cancer;    severity;    ACM;    ambulatory cough monitoring;    BRI;    Brief Reflux Inventory;    CSD;    cough severity diary;    IQR;    interquartile range;    MCLC;    Manchester Cough in Lung Cancer;    VAS;    visual analog scale;   

DOI  :  10.1016/j.chest.2018.10.003

学科分类：呼吸医学

来源: American College of Chest Physicians

【 摘 要 】

Background Cough is common in patients with lung cancer, and current antitussive treatments are suboptimal. There are little published data describing cough in patients with lung cancer or work assessing clinical associations. The aim of this study is to fill that gap. Methods This was a longitudinal prospective observational single-cohort study over 60 days. Patients were assessed through self-reported validated scales and, in a subsample, ambulatory cough monitoring at study entry (day 0), day 30, and day 60. Results At study entry, 177 patients were included and 153 provided data at day 60. The median duration of cough was 52 weeks (interquartile range, 8.5-260). Cough was described as severe enough to warrant treatment in 62% of the patients. Depending on the scale used, performance status was associated with both cough severity and cough impact (P P = .02), asthma (P = .035), and reflux disease (P P = .018). Cancer characteristics (ie, cancer stage, histology) were not associated with cough severity nor cough impact; neither was smoking or COPD. Conclusions This is the first study to describe characteristics of cough in patients with lung cancer and to identify clinical associations that may be relevant for its treatment. Our data suggest that cough is a frequent and distressing symptom and an unmet clinical need. Its association with gastrointestinal symptoms in this study may improve our understanding of pathophysiology and therapeutic options for cough occurring in patients with lung cancer.

【 授权许可】

CC BY